HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global leader ...

Adaptimmune Therapeutics’ lete-cel data achieves primary endpoint in pivotal phase 2 IGNYTE-ESO trial: Philadelphia Friday, November 15, 2024, 13:00 Hrs [IST] Adaptimmune Therap ...

Dupixent has been approved for CSU in Japan and the United Arab Emirates (UAE) and is also under regulatory review in the European Union based on earlier trial readouts. Outside of Japan and the UAE, ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Shares of Omeros touched a 52-week high, a day after the company said it could resubmit its biologics license application for narsoplimab to the Food and Drug Administration. In Thursday afternoon ...

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited is making strides in the development and potential commercialization of ...

today announced the initiation of its Biologics License Application (BLA) submission to the Drug Regulatory Authority of Pakistan (DRAP) for the conditional approval of its PIKA rabies vaccine ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

The FDA has previously granted orphan drug designation to VCN-01 in this indication. If a Biologics License Application for VCN-01 for the treatment of retinoblastoma is ultimately approved by the FDA ...